Systemic mastocytosis with associated acute myelogenous leukemia.
We present a case of a 62-year-old woman who was diagnosed with SM-AML. After initial treatment with a standard regimen of cytosine arabinoside (Ara-C)/idarubicin, her bone marrow showed residual blasts. She was subsequently treated with a second induction regimen of clofarabine and high-dose Ara-C, which resulted in remission of AML, although a residual mast cell infiltrate persisted in her bone marrow. After consolidation therapy with clofarabine/Ara-C, the patient received a stem cell allograft. A follow-up bone marrow showed no residual blasts but persistent mast cells occupying about 5% of the marrow volume.
PMID: 24381396 [PubMed]
Source: Baylor University Medical Center Proceedings - Category: Universities & Medical Training Authors: Zhrebker L, Cooper B, Krause JR Tags: Proc (Bayl Univ Med Cent) Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Bone Graft | Hematology | Leukemia | Middle East Health | Stem Cell Therapy | Stem Cells | Universities & Medical Training